Application Type
Invention
Application SubType
Invention PCT
(10) Registration Number and Date
Status
893/${sta2}
(180) Expiration Date
(20) Filing Number and Date
PH 1/2024/552646 2023.12.18
(40) Publication Number and Date
PH 1/2024/552646
U3
2025.05.05
(86) PCT Filing Number and Date
(87) PCT Publication Number and Date
(85) National Entry Date
(30) Priority Details
(72) Inventor
(EN) HE, Chuanyu : No. 221, Lantian Road, New Urban Area Urumqi
(EN) HE, Sun : No. 221, Lantian Road, New Urban Area Urumqi
(74) Representative Name
(EN) VASQUEZ BRETAÑA & SIBAL-PULIDO LAW OFFICES : NO. 7 SHERIDAN STREET, HIGHWAY HILLS
(54) Title
(EN) BRUCELLOSIS CELL IMMUNE PROTEIN AND USE THEREOF
(57) Abstract
(EN)

Provided are a Brucellosis cell immune protein and the use thereof. In the present invention, firstly, a Brucella protein with relatively high immunogenicity is screened by means of antibody spectrum technology; then, the protein gene sequence of Brucella and the T cell epitope and antigen gene sequence of Brucella are subjected to fusion and expression by using molecular biology technology, so as to improve the ability for producing an immune response which is induced by an antigen; next, the antigen is expressed in vitro and then subjected to multi-stage purification, and the obtained purified protein is used as a stimulant; and finally, anti-coagulated blood from an immunized animal is collected, the stimulant is added thereto, the mixture is incubated for 24 hours at 37°C , the resulting product is centrifuged to collect a supernatant, and the level of IL-17 in the supernatant is detected by means of an ELISA method. By means of preparing the Brucellosis cell immune protein into a reagent for detecting the level of IL-17, and then detecting IL-17 by means of an ELISA method, the level of protection for animals after immunization with a Brucella vaccine can be effectively evaluated; and the present invention involves simple operation and is accurate, and the problem of it not being possible to rapidly evaluate the level of vaccine protection after immunization with the Brucella vaccine is solved.

(58) Citations
Document Type Date Action
Event NameDateStatus
Filing2023.12.18Filed
PCT National Phase Entry2024.11.05PCT National Phase
Publication2025.05.05PUBLISHED
-2025.05.05893